Wall Street analysts forecast that Alliqua Biomedical Inc (NASDAQ:ALQA) will post earnings per share of ($0.02) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical reported earnings of ($0.79) per share during the same quarter last year, which indicates a positive year over year growth rate of 97.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 8th.
On average, analysts expect that Alliqua Biomedical will report full-year earnings of $5.14 per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.09) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Alliqua Biomedical.
Alliqua Biomedical (NASDAQ:ALQA) last posted its earnings results on Friday, August 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.64). The business had revenue of $0.86 million during the quarter. Alliqua Biomedical had a negative net margin of 99.08% and a negative return on equity of 169.35%.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Featured Story: Market Capitalization and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.